Understanding Myxoid Glioneuronal tumor: Diagnosis and Treatment

What Is a Myxoid Glioneuronal Tumor?

A myxoid glioneuronal tumor (MGT) is a newly described, rare central nervous system neoplasm. It is part of a group of tumors known as mixed neuronal-glial tumors, which contain both glial (specialized brain cells) and neuronal cells. These tumors are classified based on their histopathological architecture characterized by a myxoid (gel-like) stroma containing neuronal and glial cells. One of the common locations of such tumors is the septum pellucidum, a thin structure between the lateral ventricles (two large cavities in the brain that produce and contain cerebrospinal fluid, located in each cerebral hemisphere). They sometimes closely resemble dysembryoplastic neuroepithelial tumors (DNT) owing to their histological features.

What Are the Clinical Features of Myxoid Glioneuronal Tumors?

Patients with myxoid glioneuronal tumors that may be located in the septum pellucidum or corpus callosum exhibit symptoms that are determined by the size, growth, and location of the tumors inside the brain. Common symptoms include:

Headaches.

Seizures.

Nausea and vomiting.

Numbness or tingling, as in the case of motor or sensory weakness, visual disturbances in an optic pathway glioma ( slow-growing brain tumor that affects the optic nerves, potentially causing vision loss and often associated with neurofibromatosis type 1.), ataxia in the case of cerebellar tumors (growths in the cerebellum, the part of the brain that controls balance and coordination, which can lead to symptoms like unsteady gait and difficulty with fine motor skills), or cranial nerve palsies (involve the impairment of one or more of the twelve cranial nerves, resulting in symptoms such as facial paralysis, double vision, or loss of taste, depending on the nerve affected).

Cognitive disturbances.

Because of their position in relation to the lateral ventricle and the areas of periventricular white matter, these tumors may also cause raised intracranial tension (pressure within the head or cranium), which can have a host of secondary effects, including hydrocephalus (a condition characterized by an abnormal buildup of cerebrospinal fluid (CSF) in the ventricles of the brain, which can increase pressure inside the skull).

How Is a Myxoid Glioneuronal Tumor Diagnosed?

Diagnosis of myxoid glioneuronal tumor is made by clinical assessment, imaging studies, and molecular analysis.

1. Imaging Studies:

MRI (Magnetic Resonance Imaging): MRI is the most effective imaging tool to diagnose myxoid glioneuronal tumors. These tumors, particularly those arising within septa pellucida or about the lateral ventricle are well-defined round lesions that may show solid and cystic areas in some instances. They said that peritumoral edema and contrast enhancement indicate malignancy.

CT (Computed Tomography) Scan: Sometimes, CT scans are performed; however, in this case, the images are less informative. They show low density due to the myxoid matrix but are not the tumor markers of choice because they reveal the surrounding area well but not the core area.

2. Histopathological Examination: However, a biopsy is necessary for a definite diagnosis. Microscopically, these tumors are characterized by a myxoid background containing glial and neuronal cells. Rarely do they resemble other DNT-like tumors, namely those of the septum pellucidum or other types of septal DNTs. The identification of glial fibrillary acidic protein (GFAP) for glial elements and synaptophysin for neuronal cells are used for differential diagnosis of MGTs with other neoplasms.

3. Molecular and Genetic Markers: New molecular neuropathology and neuro-oncology knowledge has detected myxoid glioneuronal tumors' mutations. Extraordinary PDGFRA (platelet-derived growth factor receptor alpha) is the genetic change also identified in other CNS tumors. When in doubt, PCR (polymerase chain reactions) and other laboratory tests that include PDGFRA can help confirm the disease. Molecular classification is also helped by such molecular markers as the PRKCA (protein kinase C alpha (PKCα) enzyme) gene fusion being discovered in these tumors.

What Are the Challenges in Diagnosing Myxoid Glioneuronal Tumors?

The diagnosis of myxoid glioneuronal tumors is complicated by nonspecific histopathological features and the rarity of these tumors, which sometimes may be confused with similar central nervous system tumors DNT, low-grade gliomas. Furthermore, the myxoid matrix causes problems in differentiation from other myxoid-rich tumors like chordomas (slow-growing tumors that develop along the spine or skull base) or schwannomas (benign tumors that arise from the Schwann cells surrounding the nerve). Another challenge with this type of lesion is that periventricular white matter is often involved and is usually located near the corpus callosum (a large band of nerve fibers that connects the left and right hemispheres of the brain, facilitating communication between them).

What Are the Treatment Options for Myxoid Glioneuronal Tumors?

Management of myxoid glioneuronal tumors requires no less than a combination of surgery, radiation therapy, and sometimes chemotherapy.

1. Surgical Resection:

Primary Treatment Modality: It is noteworthy that surgery is the primary treatment method despite other treatment approaches. As such, these tumors are typically infiltrating and localized in areas such as septum pellucidum, where a total resection can be accomplished.

Benefits of Surgery: Tumor resection reduces mass effect-related complaints; temporal lobe tumors, for example, may cause seizures and headaches. Surgery has an added advantage in that complete resection lowers the possibility of a relapse.

Complications: The surgical risks are higher if tumors are located close to the vital structures, including the lateral ventricle or corpus callosum; if there is any injury to this location, then the patient will develop severe neurological complaints.

2. Radiotherapy:

Adjuvant Therapy: However, if complete surgical removal of the tumor is not feasible or if it reoccurs, radiotherapy can be applied. Stereotactic radiosurgery (SRS) or fractionated radiotherapy may assist in managing tumor growth, especially in eloquent brain regions.

Side Effects: Radiation doses to the periventricular white matter and the corpus callosum can lead to cognitive impairment; hence, the right amount of radiation is done in the right location.

3. Chemotherapy:

Limited Use: Chemotherapy is not the first approach taken to this type of tumor, known as myxoid glioneuronal tumor. However, they may be used in cases where the disease is more aggressive or recurrent, perhaps transforming into a malignant form. Chemotherapeutic agents, such as Temozolomide, may be useful in treating gliomas.

What Is the Prognosis for Patients with Myxoid Glioneuronal Tumors?

Myxoid glioneuronal tumors are associated with relatively good outcomes in the affected patients and tend to be improved if the tumors are completely removed. These tumors are of low grade and are not prone to transformation into malignant tumors. However, recurrence is possible, especially if the tumor is sited at the septum pellucidum or periventricular white matter.

Long-term Survival:

Patients with fully resected tumors can survive for a long time, with most of them surviving for more than five years after treatment.

This is because the follow-up strategy for these tumors is MRI at six monthly intervals, and the disease is known to progress slowly.

Quality of Life:

Patients usually recover well after treatment, either normal or nearly normal. Sequelae are likely to manifest if the surgery or tumor expansion invades the regions such as the lateral ventricle or corpus callosum.

What Are the Latest Advancements in Research for Myxoid Glioneuronal Tumors?

Lately, with the help of molecular profiling, the knowledge and management of myxoid glioneuronal tumors have improved greatly. Key areas of research include:

1. Molecular Targeting:

PDGFRA Pathway: Thus, the platelet-derived growth factor receptor alpha (PDGFRA) mutation that characterizes myxoid glioneuronal tumors has been used to develop new treatments. Drugs within developmental stages currently target this receptor.

PRKCA Fusion: Detecting PRKCA gene fusion in these tumors provides an opportunity to make personalized medicine, thereby giving better and less toxic treatment.

2. Immunotherapy:

Checkpoint inhibitors have been developed as possible treatments. They mobilize the patient’s immune system, which is found to promote the malignant transformation of the tumor.

3. Advanced Imaging Techniques:

Functional MRI (fMRI): As a result, functional MRI and diffusion tensor imaging (DTI) are being used to enhance the outcomes of surgeries that involve the removal of tumors, such as those located in the corpus callosum.

PET Scans: PET scans have been attempted to incorporate the metabolic activity of tumors in an attempt to distinguish between low-grade myxoid glioneuronal tumors and more malignant neoplasms.

Conclusion

Myxoid glioneuronal tumors are unusual kinds of primary brain tumors that can be found near the septum pellucidum, the lateral ventricle, or, principally, in periventricular white matter. Molecular neuropathology and molecular neuro-oncology have given a better understanding of these tumors, especially with mutations like PDGFRA and PRKCA gene fusion. Although complete surgical resection is the optimal treatment for curative intent, which provides the highest long-term survival rate, ongoing efforts to identify molecular therapies appear to provide greater chances of enhancing patient survival in the future. Closely coordinated care and frequent follow-up are still required to address this challenging disease.